CLOs on the Move

Nicka and Associates

www.nicka-associates.com

 
Nicka & Associates, Inc is a Plano, TX-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Community Medical Center, Inc

CMC's Department of Pediatrics and the hospital's administration are committed to quality care for children, said Steve Carlson, CMC's president and chief executive officer.

Sybron Dental Specialties, Inc.

Sybron Dental Specialties, Inc. is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Anaheim, CA. To find more information about Sybron Dental Specialties, Inc., please visit www.sybrondental.com

Indian Health Care Resource Center of Tulsa

Indian Health Care Resource Center of Tulsa is a Tulsa, OK-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ImprimisRx

ImprimisRx® is a pharmaceutical company dedicated to delivering high-quality and innovative medicines to physicians and patients at affordable prices. We are pioneering a new commercial pathway in the pharmaceutical industry, using compounding pharmacies for the formulation and distribution of high-quality formulations that are supported by the clinical experience of physicians and their patients. We offer proprietary compounded ophthalmic formulations. All of our innovative drug formulations are born from the clinical experience of physicians and pharmacist formulators. We are focused on people, and believe our unique business model provides us with the opportunity to address unmet patient needs while delivering high quality and affordable medical solutions to physicians and patients.

ProKidney

ProKidney, a pioneer in the treatment of chronic kidney disease (CKD) through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney`s lead product candidate, REACT® (Renal Autologous Cell Therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of CKD, but in some cases drive meaningful improvement in kidney function. REACT® has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting an immediate start to a global registrational program, which launched in the United States on schedule in January 2022. On January 18, 2022, ProKidney announced that it would become a publicly traded company via a business combination with Social Capital Suvretta Holdings Corp. III